Anti-Fibrinolytic Drugs - Eastern Africa

The Anti-Fibrinolytic Drugs market in Eastern Africa is expected to witness a significant increase in revenue, reaching a projected value of US$28.46m in 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 5.20% from 2024 to 2029, resulting in a market volume of US$36.67m by 2029.
In comparison to other regions worldwide, United States is projected to generate the highest revenue in the Anti-Fibrinolytic Drugs market, with an estimated value of US$9.86bn in 2024.
Eastern Africa is experiencing a growing demand for anti-fibrinolytic drugs, driven by an increasing prevalence of bleeding disorders in the region.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Eastern Africa has been experiencing steady growth in recent years.

Customer preferences: One of the main reasons for this growth is the increasing demand for these drugs among the aging population in the region. As life expectancy continues to rise, more people are experiencing age-related health issues, including bleeding disorders that require anti-fibrinolytic drugs to manage. Additionally, the prevalence of chronic diseases such as cancer and cardiovascular disease also contributes to the demand for these drugs.

Trends in the market: In countries such as Kenya and Tanzania, there has been a shift towards the use of generic versions of these drugs as opposed to brand-name options. This trend is driven by the lower cost of generic drugs, which makes them more accessible to a wider population. Another trend in the market is the increasing focus on research and development of new anti-fibrinolytic drugs that are more effective and have fewer side effects.

Local special circumstances: In some countries in Eastern Africa, there are challenges with the distribution and availability of these drugs, particularly in rural areas. This is due to inadequate healthcare infrastructure and limited resources. Additionally, there is a lack of awareness among the general population about the importance of these drugs in managing bleeding disorders, which can lead to underutilization.

Underlying macroeconomic factors: The healthcare sector in Eastern Africa is undergoing significant growth and development, with increased investment in healthcare infrastructure and the expansion of healthcare services. This growth is supported by favorable government policies and initiatives aimed at improving access to healthcare for the population. Additionally, the region is experiencing economic growth, which has led to an increase in disposable income and healthcare spending. These factors are expected to continue driving the growth of the anti-fibrinolytic drugs market in the region.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.